NBIX Neurocrine Biosciences, Inc. - Common Stock

NASDAQ · Biotechnology · Ver en SEC EDGAR ↗
$154,36
Precio · Ago 18, 2026
Fundamentales a fecha de Jul 31, 2026
Rango 52S
$123–$186
50% of range
Calificación del Analista
BUY
36 analysts
Precio Objetivo
$212
+37% upside
P/E (TTM)
33.1
ROE
16.1%
Margen de Beneficio Neto
16.7%

Acerca de Neurocrine Biosciences, Inc. - Common Stock Descripción general de la empresa de Wikipedia

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Leer más

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

NBIX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

Precio
$154.36
Capitalización Bursátil
$15.45B
P/E (TTM)
33.1
BPA (TTM)
$4.67
Ingresos (TTM)
$2.86B
Rendimiento div.
—
ROE
16.1%
Deuda/Capital
—
Rango 52S
$123 – $186

NBIX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

Ingresos y Beneficio Neto $2.86B
10-point trend, +18970.0%
2016-12-31 → 2025-12-31
BPA $4.67
10-point trend, +386.5%
2016-12-31 → 2025-12-31
Flujo de caja libre $749M
10-point trend, +778.9%
2016-12-31 → 2025-12-31
Márgenes 16.7%

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares
P/E (TTM)
5-point trend, -67.2%
33.1
16.9
P/S (TTM) (P/V (TTM))
5-point trend, -30.4%
5.4
9.6
P/B (P/C)
5-point trend, -25.8%
4.7
7.7
Price / FCF (Precio / FCF)
5-point trend, -45.3%
20.6
—

Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares
Operating Margin (Margen Operativo)
5-point trend, +139.4%
21.6%
—
Net Profit Margin (Margen de Beneficio Neto)
5-point trend, +111.8%
16.7%
-36.9%
ROA
5-point trend, +143.3%
11.5%
-21.8%
ROE
5-point trend, +144.2%
16.1%
-47.3%
ROIC
5-point trend, +95.9%
12.9%
—

Salud financiera Deuda, liquidez, solvencia — solidez del balance general

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares
Current Ratio (Ratio corriente)
5-point trend, -14.3%
3.4
3.5
Quick Ratio (Ratio Rápido)
5-point trend, -48.4%
1.9
—

Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares
Revenue YoY (Ingresos interanuales)
5-point trend, +152.4%
21.4%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
5-point trend, +152.4%
24.3%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
5-point trend, +152.4%
22.3%
—
EPS YoY (EPS interanual)
5-point trend, +407.6%
41.9%
—
Net Income YoY (Beneficio Neto interanual)
5-point trend, +434.2%
40.2%
—

Métricas por acción BPA, valor contable por acción, flujo de caja por acción, dividendo por acción

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares
EPS (Diluted) (BPA (Diluido))
5-point trend, +407.6%
$4.67
—

Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar

Métrica
Tendencia a 5 años
NBIX
Mediana de Pares

NBIX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

COMPRA 36 analistas
  • Compra fuerte 14 38,9%
  • Compra 17 47,2%
  • Mantener 5 13,9%
  • Venta 0 0,0%
  • Venta fuerte 0 0,0%

Precio objetivo a 12 meses

27 analistas · 2026-08-15
Objetivo mediano $215.00 +39,3%
Objetivo medio $211.57 +37,1%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

Sorpresa Media
0.24%
Período EPS Actual EPS est. Sorpresa
30 de junio de 2026 $1.39 $1.37 0.02%
31 de marzo de 2026 $1.91 $1.20 0.71%
31 de diciembre de 2025 $1.91 $1.20 0.71%
30 de septiembre de 2025 $2.04 $1.62 0.42%
30 de junio de 2025 $1.06 $0.99 0.07%
31 de marzo de 2025 $0.08 $0.56 -0.48%

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
NBIX $14.20B 30.4 21.4% 16.7% 16.1% —
INSM $37.29B -27.1 66.7% -210.5% -128.4% —
MRNA $11.62B -4.1 -39.9% -145.2% -31.3% —
INCY $19.60B 15.4 21.2% 25.0% 27.6% —
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
BBIO $14.90B -20.2 126.3% -146.0% 41.2% —
BMRN $11.43B 33.0 12.9% 10.8% 5.8% —
EXEL $11.44B 15.7 7.0% 33.7% 37.3% —
ARWR $4.68B -3449.0 23258.2% -0.20% -0.50% —
MDGL $13.30B -45.3 432.1% -30.1% -44.4% —
HALO $7.93B 26.3 37.5% 22.7% 166.1% —

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

Estado de resultados 17
Datos anuales de Estado de resultados para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Cost of Revenue 10-point trend, +52100000.00 $52M $34M $40M $23M $14M $10M · $5M $1M $0 $0 ·
R&D Expense 5-point trend, +245.8% · · · · · · · $161M $122M $94M $81M $46M
SG&A Expense 12-point trend, +6328.3% $1.16B $1.01B $888M $753M $583M $433M $354M $249M $170M $68M $32M $18M
Operating Expenses 12-point trend, +3379.8% $2.24B $1.78B $1.64B $1.24B $1.03B $883M $716M $414M $293M $162M $114M $64M
Operating Income 12-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M $-94M $-64M
Interest Expense 9-point trend, +4600000.00 · · $5M $7M $26M $33M $32M $30M $20M $0 $0 ·
Interest Income 3-point trend, +351.2% · · · · · · · · · $3M $2M $629.0K
Other Non-op 12-point trend, +479344.4% $86M $-84M $81M $-35M $-1M $-56M $-26M $-15M $-11M $6M $20.0K $18.0K
Pretax Income 10-point trend, +600.0% $705M $486M $332M $214M $101M $107M $46M $22M $-143M $-141M · ·
Income Tax 12-point trend, +226800000.00 $227M $145M $82M $59M $12M $-301M $10M $700.0K $0 $0 $0 $0
Net Income 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
EPS (Basic) 12-point trend, +693.8% $4.81 $3.40 $2.56 $1.61 $0.95 $4.38 $0.40 $0.23 $-1.62 $-1.63 $-1.05 $-0.81
EPS (Diluted) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
Shares (Basic) 12-point trend, +33.4% 99,500,000 100,400,000 97,700,000 95,800,000 94,600,000 93,100,000 91,600,000 90,200,000 88,089,000 86,713,000 84,496,000 74,577,000
Shares (Diluted) 12-point trend, +37.4% 102,500,000 103,700,000 101,000,000 98,900,000 97,900,000 97,800,000 95,700,000 95,400,000 88,089,000 86,713,000 84,496,000 74,577,000
EBITDA 11-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M · $-64M
Balance general 28
Datos anuales de Balance general para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +2199.0% $713M $233M $251M $263M $341M $187M $112M $142M $255M $83M $74M $31M
Short-term Investments 8-point trend, +127.6% · · · · $370M $614M $558M $509M $261M $224M $305M $163M
Receivables 10-point trend, +686800000.00 $687M $479M $439M $350M $186M $157M $127M $57M $31M $0 · ·
Inventory 10-point trend, +69000000.00 $69M $57M $38M $35M $30M $28M $17M $11M $1M $0 · ·
Prepaid Expense 2-point trend, +252.0% $171M $48M · · · · · · · · · ·
Other Current Assets 12-point trend, +2535.4% $116M $64M $98M $79M $46M $30M $17M $19M $7M $3M $5M $4M
Current Assets 12-point trend, +1172.8% $2.52B $1.72B $1.61B $1.45B $973M $1.02B $831M $738M $555M $310M $384M $198M
PP&E (Net) 12-point trend, +3482.0% $90M $83M $71M $59M $59M $45M $42M $34M $11M $6M $3M $3M
PP&E (Gross) 12-point trend, +565.9% $208M $189M $154M $125M $110M $86M $76M $62M $38M $32M $30M $31M
Accum. Depreciation 12-point trend, +311.5% $118M $106M $83M $66M $52M $42M $34M $28M $28M $26M $27M $29M
Goodwill 5-point trend, +6100000.00 $6M $6M $6M $5M $0 · · · · · · ·
Intangibles 5-point trend, +4700000.00 $5M $36M $36M $37M $0 · · · · · · ·
Other Non-current Assets 7-point trend, +48700000.00 $49M $52M $50M $25M $4M $6M $0 · · · · ·
Total Assets 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Accounts Payable 12-point trend, +274005.7% $674M $462M $449M $348M $226M $169M $141M $86M $6M $5M $3M $246.0K
Accrued Liabilities 3-point trend, +83.3% · · · · · · · · · $21M $19M $12M
Current Liabilities 12-point trend, +4645.9% $743M $508M $655M $538M $246M $186M $565M $88M $54M $30M $26M $16M
Capital Leases 8-point trend, +415300000.00 $415M $455M $258M $94M $105M $94M $87M $0 · · · ·
Deferred Tax $0 · · · · · · · · · · ·
Other Non-current Liabilities 12-point trend, +84400.0% $220M $166M $106M $30M $12M $10M $17M $36M $0 $113.0K $221.0K $260.0K
Total Liabilities 12-point trend, +3914.7% $1.38B $1.13B $1.02B $661M $698M $608M $669M $512M $445M $50M $50M $34M
Common Stock 12-point trend, +31.6% $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $91.0K $89.0K $87.0K $86.0K $76.0K
Paid-in Capital · · · · · · · · · · · $1.04B
Retained Earnings 12-point trend, +154.2% $448M $29M $-157M $-407M $-636M $-725M $-1.13B $-1.18B $-1.20B $-1.06B $-915M $-826M
AOCI 12-point trend, +4829.2% $13M $6M $7M $-8M $-2M $2M $1M $-2M $-2M $-318.0K $-977.0K $-277.0K
Stockholders' Equity 12-point trend, +1458.8% $3.25B $2.59B $2.23B $1.71B $1.37B $1.13B $637M $481M $372M $315M $424M $209M
Liabilities + Equity 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Shares Outstanding 12-point trend, +30.9% 100,100,000 99,400,000 98,700,000 96,500,000 94,900,000 93,500,000 92,300,000 90,797,000 88,793,903 86,883,300 86,262,594 76,465,942
Flujo de Efectivo 15
Datos anuales de Flujo de Efectivo para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
D&A 5-point trend, +386.6% · · · · · · · $4M $2M $1M $1M $827.0K
Stock-based Comp 12-point trend, +1998.8% $218M $196M $194M $173M $134M $100M $75M $58M $43M $28M $28M $10M
Deferred Tax 8-point trend, +164200000.00 $164M $-123M $-61M $22M $6M $-311M $0 $0 · · · ·
Amort. of Intangibles 6-point trend, +4100000.00 $4M $4M $4M $500.0K $0 $0 · · · · · ·
Operating Cash Flow 12-point trend, +1760.4% $783M $595M $390M $339M $256M $228M $147M $101M $-94M $-106M $-38M $-47M
CapEx 12-point trend, +2009.2% $34M $38M $28M $16M $23M $11M $15M $25M $7M $4M $2M $2M
Investing Cash Flow 10-point trend, -334.1% $-264M $-127M $-467M $-177M $-130M $4M $-211M $-243M $-251M $113M · ·
Stock Issued 12-point trend, -6.7% $129M $122M $65M $45M $28M $29M $32M $30M $14M $2M $277M $139M
Stock Repurchased 4-point trend, +167700000.00 $168M $300M $0 $0 · · · · · · · ·
Net Stock Activity 11-point trend, -127.6% $-38M $-178M $65M $45M $28M $29M $27M $30M $14M $2M · $139M
Financing Cash Flow 10-point trend, -1702.5% $-38M $-487M $65M $-234M $27M $-158M $32M $30M $517M $2M · ·
Net Change in Cash 12-point trend, +3584.6% $480M $-18M $-12M $-73M $154M $75M $-32M $-112M $171M $9M $43M $-14M
Taxes Paid $81M · · · · · · · · · · ·
Free Cash Flow 11-point trend, +1635.7% $749M $557M $362M $323M $233M $218M $137M $77M $-101M $-110M · $-49M
Levered FCF 6-point trend, +661.3% · · $358M $318M $210M $92M $112M $47M · · · ·
Rentabilidad 7
Datos anuales de Rentabilidad para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Operating Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
Net Margin 10-point trend, +101.8% 16.7% 14.5% 13.2% 10.4% 7.9% 38.9% 4.7% 4.7% -88.2% -940.6% · ·
Pretax Margin 8-point trend, +409.5% 24.7% 20.6% 17.6% 14.4% 8.9% 10.2% 5.9% 4.8% · · · ·
EBITDA Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
ROA 11-point trend, +137.6% 11.5% 9.8% 8.9% 7.0% 4.7% 26.8% 3.2% 2.3% -24.1% -33.6% · -30.4%
ROE 11-point trend, +143.7% 16.1% 12.9% 11.8% 9.5% 6.6% 42.2% 6.1% 4.5% -41.5% -38.2% · -36.8%
ROIC 8-point trend, +74.0% 12.9% 15.5% 8.5% 10.5% 6.6% 55.2% 9.0% 7.4% · · · ·
Liquidez y Solvencia 3
Datos anuales de Liquidez y Solvencia para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, -73.2% 3.4 3.4 2.5 2.7 4.0 5.4 1.5 8.4 10.2 10.2 · 12.7
Quick Ratio 11-point trend, -84.8% 1.9 1.4 1.1 1.1 3.6 5.1 1.4 2.2 10.1 10.1 · 12.4
Interest Coverage 7-point trend, +910.6% · · 54.5 35.1 4.0 5.0 2.3 1.2 -6.7 · · ·
Eficiencia 3
Datos anuales de Eficiencia para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +0.69 0.7 0.7 0.7 0.7 0.6 0.7 0.7 0.5 0.3 0.0 · 0.0
Inventory Turnover 5-point trend, +0.2% 0.8 0.7 1.1 0.7 · · · 0.8 · · · ·
Receivables Turnover 9-point trend, -52.7% 4.9 5.1 4.8 5.6 6.6 7.4 8.6 10.3 10.4 · · ·
Por Acción 5
Datos anuales de Por Acción para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, +1090.7% $32.50 $26.05 $22.61 $17.70 $14.48 $12.04 $6.90 $5.29 $4.19 $3.62 · $2.73
Revenue / Share 11-point trend, +27.91 $27.91 $22.71 $18.68 $15.05 $11.58 $10.69 $8.23 $4.73 $1.83 $0.17 · $0.00
Cash Flow / Share 11-point trend, +1308.1% $7.64 $5.74 $3.86 $3.43 $2.62 $2.34 $1.59 $1.06 $-1.07 $-1.22 · $-0.63
Cash / Share 11-point trend, +1656.1% $7.12 $2.34 $2.54 $2.72 $3.59 $2.00 $1.22 $1.56 $2.87 $0.96 · $0.41
EPS (TTM) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
Tasas de Crecimiento 9
Datos anuales de Tasas de Crecimiento para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, +156.0% 21.4% 24.8% 26.8% 31.3% 8.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +11.9% 24.3% 27.6% 21.7% · · · · · · · · ·
Revenue CAGR 5Y 22.3% · · · · · · · · · · ·
EPS YoY 5-point trend, +153.9% 41.9% 33.2% 58.3% 69.6% -77.9% · · · · · · ·
EPS CAGR 3Y 3-point trend, +376.6% 44.1% 52.9% -16.0% · · · · · · · · ·
EPS CAGR 5Y 2.3% · · · · · · · · · · ·
Net Income YoY 5-point trend, +151.6% 40.2% 36.7% 61.6% 72.4% -78.0% · · · · · · ·
Net Income CAGR 3Y 3-point trend, +404.1% 45.8% 56.2% -15.0% · · · · · · · · ·
Net Income CAGR 5Y 3.3% · · · · · · · · · · ·
Valoración (TTM) 10
Datos anuales de Valoración (TTM) para NBIX
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Net Income TTM 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
Market Cap 11-point trend, +731.1% $14.20B $13.57B $13.00B $11.53B $8.08B $8.96B $9.92B $6.48B $6.89B $3.36B · $1.71B
P/E 12-point trend, +210.1% 30.4 41.5 53.3 76.6 92.6 23.0 275.6 324.6 -47.9 -23.7 -53.9 -27.6
P/S 10-point trend, -97.8% 5.0 5.8 6.9 7.7 7.1 8.6 12.6 14.4 42.6 224.2 · ·
P/B 11-point trend, -46.7% 4.4 5.2 5.8 6.7 5.9 8.0 15.6 13.5 18.5 10.7 · 8.2
P / Tangible Book 6-point trend, -45.2% 4.4 5.3 5.9 6.9 5.9 8.0 · · · · · ·
P / Cash Flow 11-point trend, +150.1% 18.1 22.8 33.4 34.0 31.5 39.2 65.2 64.0 -73.0 -31.7 · -36.2
P / FCF 11-point trend, +154.1% 19.0 24.4 36.0 35.7 34.7 41.2 72.2 84.7 -68.0 -30.5 · -35.0
Earnings Yield 12-point trend, +190.6% 3.3% 2.4% 1.9% 1.3% 1.1% 4.3% 0.36% 0.31% -2.1% -4.2% -1.9% -3.6%

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

Estado de resultados
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $2.86B$2.36B$1.89B$1.49B$1.13B
Margen Operativo % 21.6%24.2%13.3%16.7%9.0%
Beneficio neto $479M$341M$250M$154M$90M
EPS Diluido $4.67$3.29$2.47$1.56$0.92
Balance general
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ratio corriente 3.43.42.52.74.0
Ratio Rápido 1.91.41.11.13.6
Flujo de Efectivo
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flujo de caja libre $749M$557M$362M$323M$233M

Últimas noticias Noticias recientes que mencionan a esta empresa

Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

📊

Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Propietarios institucionales (13F) 827 declarantes · $10.1B total · A fecha de 30 de junio de 2026

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
153 (+61 vs trimestre anterior) 62 (-37 vs trimestre anterior) 300 (+11 vs trimestre anterior) 223 (+8 vs trimestre anterior) +9.4M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
Dodge & Cox $941 218 594 5 584 707 9,32% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $838 307 078 4 974 083 8,30% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $766 048 708 4 545 339 7,59% Acciones
STATE STREET CORP $739 126 759 4 385 598 7,32% Acciones
RENAISSANCE TECHNOLOGIES LLC $393 680 402 2 335 897 3,90% Acciones
TWO SIGMA INVESTMENTS, LP $349 922 479 2 076 260 3,47% Acciones
Vestal Point Capital, LP $316 845 800 1 880 000 3,14% Acciones
GEODE CAPITAL MANAGEMENT, LLC $294 151 210 1 750 392 2,91% Acciones
RTW INVESTMENTS, LP $213 689 740 1 267 925 2,12% Acciones
NORGES BANK $164 132 866 973 880 1,63% Acciones
FIRST TRUST ADVISORS LP $155 578 851 923 125 1,54% Acciones
JACOBS LEVY EQUITY MANAGEMENT, INC $122 375 286 726 112 1,21% Acciones
TWO SIGMA ADVISERS, LP $119 504 823 842 592 1,18% Acciones
Swedbank AB $109 730 107 651 082 1,09% Acciones
VANGUARD FIDUCIARY TRUST CO $109 170 737 647 763 1,08% Acciones
DIMENSIONAL FUND ADVISORS LP $109 070 816 647 171 1,08% Acciones
VICTORY CAPITAL MANAGEMENT INC $104 238 729 618 499 1,03% Acciones
Caisse de depot et placement du Quebec $91 002 327 539 961 0,90% Acciones
ARMISTICE CAPITAL, LLC $90 307 457 535 838 0,89% Acciones
PRIMECAP MANAGEMENT CO/CA/ $82 807 988 491 340 0,82% Acciones
AMERIPRISE FINANCIAL INC $79 666 260 472 708 0,79% Acciones
Hood River Capital Management LLC $79 082 184 469 233 0,78% Acciones
ROYAL BANK OF CANADA $73 348 000 435 207 0,73% Acciones
Pictet Asset Management Holding SA $72 751 030 430 635 0,72% Acciones
Gotham Asset Management, LLC $62 622 213 371 568 0,62% Acciones
Fiera Capital Corp $61 558 083 365 254 0,61% Acciones
BlackRock, Inc. $61 129 161 362 709 0,61% Acciones
ALLIANCEBERNSTEIN L.P. $60 767 710 461 270 0,60% Acciones
Vinva Investment Management Ltd $58 838 530 346 109 0,58% Acciones
AustralianSuper Pty Ltd $58 817 535 348 993 0,58% Acciones
GOLDMAN SACHS GROUP INC $58 206 259 345 366 0,58% Acciones
BRAIDWELL LP $56 656 579 336 171 0,56% Acciones
RHUMBLINE ADVISERS $52 723 054 312 832 0,52% Acciones
Clearbridge Investments, LLC $47 391 031 281 194 0,47% Acciones
SEIZERT CAPITAL PARTNERS, LLC $46 740 991 277 337 0,46% Acciones
Swiss National Bank $45 319 062 268 900 0,45% Acciones
BARCLAYS PLC $44 228 304 262 428 0,44% Acciones
ENVESTNET ASSET MANAGEMENT INC $44 187 600 262 192 0,44% Acciones
WORLDQUANT MILLENNIUM ADVISORS LLC $44 038 027 261 299 0,44% Acciones
Candriam S.C.A. $43 932 854 260 926 0,44% Acciones
BNP PARIBAS FINANCIAL MARKETS $43 921 064 260 605 0,43% Acciones
FMR LLC $40 551 501 240 612 0,40% Acciones
PRINCIPAL FINANCIAL GROUP INC $40 285 595 239 034 0,40% Acciones
California Public Employees Retirement System $39 090 345 231 942 0,39% Acciones
RENAISSANCE GROUP LLC $38 589 515 228 970 0,38% Acciones
Assenagon Asset Management S.A. $37 516 902 222 606 0,37% Acciones
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $37 508 000 222 554 0,37% Acciones
Sumitomo Mitsui Trust Group, Inc. $36 317 270 215 488 0,36% Acciones
Carmignac Gestion $36 083 344 214 100 0,36% Acciones
PFM Health Sciences, LP $35 966 549 213 407 0,36% Acciones
Bridgewater Associates, LP $34 663 773 205 677 0,34% Acciones
LOS ANGELES CAPITAL MANAGEMENT LLC $34 304 966 203 548 0,34% Acciones
Nantahala Capital Management, LLC $33 707 000 200 000 0,33% Opción de compra
BANK OF AMERICA CORP /DE/ $32 143 164 190 721 0,32% Acciones
MORGAN STANLEY $32 058 612 190 219 0,32% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $31 213 608 185 200 0,31% Opción de venta
FULLER & THALER ASSET MANAGEMENT, INC. $30 192 001 179 149 0,30% Acciones
PRUDENTIAL FINANCIAL INC $29 909 064 177 465 0,30% Acciones
SEB Asset Management AB $29 789 208 176 754 0,30% Acciones
Ensign Peak Advisors, Inc $29 653 059 175 946 0,29% Acciones
IEQ CAPITAL, LLC $29 628 432 175 800 0,29% Acciones
MACKENZIE FINANCIAL CORP $29 609 071 175 685 0,29% Acciones
NEW YORK STATE COMMON RETIREMENT FUND $29 573 511 175 474 0,29% Acciones
Korea Investment CORP $29 154 701 172 989 0,29% Acciones
PKO BP BANKOWY Universal Pension Society JSC $28 786 115 170 802 0,29% Acciones
Zurich Insurance Group Ltd/FI $28 618 254 169 806 0,28% Acciones
Impax Asset Management Group plc $26 965 600 160 000 0,27% Acciones
Nearwater Capital Markets, Ltd $26 122 925 155 000 0,26% Acciones
Mariner, LLC $25 627 342 152 055 0,25% Acciones
Integral Health Asset Management, LLC $25 281 000 150 000 0,25% Acciones
Rock Springs Capital Management LP $24 395 441 144 750 0,24% Acciones
Zurcher Kantonalbank (Zurich Cantonalbank) $23 738 829 140 854 0,24% Acciones
Fisher Asset Management, LLC $22 769 751 135 104 0,23% Acciones
Aware Super Pty Ltd as trustee of Aware Super $22 056 175 130 870 0,22% Acciones
RAYMOND JAMES FINANCIAL INC $22 009 323 130 592 0,22% Acciones
Hudson Bay Capital Management LP $21 909 550 130 000 0,22% Acciones
Life Cycle Investment Partners Ltd $21 287 319 126 308 0,21% Acciones
VIRGINIA RETIREMENT SYSTEMS ET Al $20 937 370 147 623 0,21% Acciones
DNB Asset Management AS $20 280 996 120 337 0,20% Acciones
JANE STREET GROUP, LLC $20 072 518 119 100 0,20% Opción de venta
Sarissa Capital Management LP $19 639 889 116 533 0,19% Acciones
Andra AP-fonden $19 522 682 148 191 0,19% Acciones
AMERICAN CENTURY COMPANIES INC $19 061 140 113 099 0,19% Acciones
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $18 885 863 112 059 0,19% Acciones
Man Group plc $18 859 404 111 902 0,19% Acciones
Mitsubishi UFJ Asset Management Co., Ltd. $18 788 956 111 484 0,19% Acciones
UBS Group AG $18 243 577 108 248 0,18% Acciones
Robeco Institutional Asset Management B.V. $18 197 736 107 976 0,18% Acciones
LOOMIS SAYLES & CO L P $18 108 412 107 446 0,18% Acciones
Retirement Systems of Alabama $17 527 134 103 997 0,17% Acciones
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $17 474 389 132 643 0,17% Acciones
ING GROEP NV $17 224 277 102 200 0,17% Acciones
Legal & General Group Plc $17 176 748 101 918 0,17% Acciones
RICE HALL JAMES & ASSOCIATES, LLC $16 886 364 100 195 0,17% Acciones
Universal- Beteiligungs- und Servicegesellschaft mbH $16 827 572 99 912 0,17% Acciones
CWM, LLC $16 696 728 126 740 0,17% Acciones
CAPITAL FUND MANAGEMENT S.A. $16 536 148 98 117 0,16% Acciones
Clark Capital Management Group, Inc. $15 629 612 92 738 0,15% Acciones
Distillate Capital Partners LLC $15 604 993 92 592 0,15% Acciones
LAZARD ASSET MANAGEMENT LLC $15 399 211 91 371 0,15% Acciones

Informantes de la empresa 42 insiders · 21 directivos · 15 consejeros

Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Kyle Gano Chief Executive Officer 13 de febrero de 2025 M 139 907 0 0 $0
Matt Abernethy Chief Financial Officer 13 de febrero de 2025 M 35 810 0 0 $0
Timothy Coughlin Chief Financial Officer 6 de febrero de 2017 S 137 961 0 0 $0
David-Alexandre C Gros President & COO 6 de febrero de 2017 A — 0 0 $0
Ingrid Delaet Chief Regulatory Officer 10 de julio de 2026 M 16 225 0 5 $-3 747 962
Darin Lippoldt Chief Legal Officer 9 de julio de 2026 M 54 729 0 4 $-3 497 443
Sanjay Chandru Keswani Chief Medical Officer 2 de junio de 2026 F 1 479 0 0 $0
Julie Cooke Chief Human Resources Officer 2 de junio de 2026 M 22 374 0 1 $-2 200 685
David W. Boyer Chief Corp. Affairs Officer 13 de febrero de 2025 M 3 565 0 0 $0
Eiry Roberts Chief Medical Officer 13 de febrero de 2025 M 35 640 0 0 $0
Eric Benevich Chief Commercial Officer 13 de febrero de 2025 M 44 689 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 8 de febrero de 2023 S 42 337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 31 de enero de 2022 A 82 273 0 0 $0
Haig P. Bozigian Chief Development Officer 8 de febrero de 2021 A 157 651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 5 de febrero de 2018 A 55 946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 31 de agosto de 2011 A 118 256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 27 de febrero de 2008 A 9 667 0 0 $0
Wendall Wierenga EVP, Research & Development 19 de enero de 2006 A 5 023 0 0 $0
Henry Pan Executive VP and CMO 3 de junio de 2005 A 11 216 0 0 $0
Robert J Little SVP, Commercial Operations 18 de febrero de 2005 A — 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 18 de diciembre de 2003 S 7 966 0 0 $0
Leslie V Norwalk Consejero 29 de julio de 2026 M 2 430 0 2 $-437 584
SHERWIN STEPHEN A Consejero 5 de junio de 2026 M 15 860 0 5 $-4 132 990
William H Rastetter Consejero 27 de mayo de 2026 A 43 678 0 1 $-2 732 760
Kevin Charles Gorman Consejero 27 de mayo de 2026 A 511 293 0 1 $-37 824 431
Christine A Poon Consejero 27 de mayo de 2026 A 4 753 0 0 $0
POPS RICHARD F Consejero 27 de mayo de 2026 A 37 798 0 1 $-2 364 750
LYONS GARY A Consejero 27 de mayo de 2026 A 122 141 0 1 $-2 289 150
MORROW GEORGE J Consejero 27 de mayo de 2026 A 10 386 0 1 $-2 150 550
Johanna Mercier Consejero 22 de mayo de 2025 M 3 535 0 0 $0
Alfred Sandrock Consejero 22 de mayo de 2019 A — 0 0 $0
Corinne H Nevinny Consejero 24 de mayo de 2018 A 43 283 0 0 $0
Thomas W Mitchell Consejero 28 de mayo de 2015 A 1 000 0 0 $0
VALE WYLIE W Consejero 25 de mayo de 2011 A 231 372 0 0 $0
Adrian Adams Consejero 30 de junio de 2006 A — 0 0 $0
NEUROCRINE BIOSCIENCES INC Propietario del 10% 23 de febrero de 2023 P 8 575 316 0 0 $0
Jude Onyia — 4 de agosto de 2026 G 20 996 0 1 $-1 762 710
Shalini Sharp — 27 de mayo de 2026 A 4 088 0 0 $0
MOLLICA JOSEPH A — 22 de mayo de 2017 A 56 042 0 0 $0
HAWRAN PAUL W — 18 de septiembre de 2006 J 132 000 0 0 $0
Lawrence Steinman — 2 de marzo de 2005 S 15 500 0 0 $0
CONLON PAUL J — 16 de diciembre de 2003 S 57 335 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Activistas y propietarios del %+ 5 1 tenencia

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
Neurocrine Biosciences, Inc. ×3 presentaciones 24 de febrero de 2023 — Presentación inicial — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Propiedad de ETFs Mantenido por 129 ETFs

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
IBRN · iShares Trust 3,71% 1 793 SH 8 de agosto de 2026 Diario
PBE · Invesco Exchange-Traded Fund Trust 2,51% 55 704 SH 8 de agosto de 2026 Diario
MCOW · Pacer Funds Trust 2,17% 162 NS 30 de abril de 2026 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 2,01% 457 NS 30 de abril de 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,97% 22 094 SH 8 de agosto de 2026 Diario
SMRI · EA Series Trust 1,95% 79 947 NS 30 de abril de 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1,78% 55 458 SH 8 de agosto de 2026 Diario
XMHQ · Invesco Exchange-Traded Fund Trust 1,74% 599 955 SH 8 de agosto de 2026 Diario
BUL · Pacer Funds Trust 1,66% 16 032 NS 30 de abril de 2026 N-PORT
BBP · ETFis Series Trust I 1,38% 6 192 NS 30 de abril de 2026 N-PORT
ILDR · First Trust Exchange-Traded Fund VI… 1,29% 23 318 NS 31 de mayo de 2026 N-PORT
IBB · iShares Trust 1,22% 725 434 SH 8 de agosto de 2026 Diario
RFG · Invesco Exchange-Traded Fund Trust 1,16% 25 502 SH 8 de agosto de 2026 Diario
AGNG · Global X Funds 1,12% 5 792 NS 31 de mayo de 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 1,12% 5 472 SH 8 de agosto de 2026 Diario
LABU · Direxion Shares ETF Trust 0,95% 37 476 NS 30 de abril de 2026 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 0,93% 7 516 NS 30 de abril de 2026 N-PORT
IVOG · VANGUARD ADMIRAL FUNDS 0,89% 99 214 SH 8 de agosto de 2026 Diario
FXH · First Trust Exchange-Traded AlphaDE… 0,87% 57 454 NS 30 de abril de 2026 N-PORT
IJK · iShares Trust 0,86% 588 275 SH 8 de agosto de 2026 Diario
COWG · Pacer Funds Trust 0,81% 132 963 NS 30 de abril de 2026 N-PORT
BIB · ProShares Trust 0,80% 3 712 NS 31 de mayo de 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0,79% 57 321 SH 8 de agosto de 2026 Diario
TMFX · RBB Fund, Inc. 0,76% 1 542 NS 31 de mayo de 2026 N-PORT
ABOT · Abacus FCF ETF Trust 0,72% 240 NS 30 de abril de 2026 N-PORT
CLSE · Trust for Professional Managers 0,66% 25 529 NS 31 de mayo de 2026 N-PORT
MIDE · DBX ETF Trust 0,64% 136 NS 29 de mayo de 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,63% 533 NS 30 de abril de 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,55% 13 166 NS 30 de abril de 2026 N-PORT
SMDX · Tidal Trust III 0,55% 5 215 NS 30 de abril de 2026 N-PORT
XJH · iShares Trust 0,51% 13 589 SH 8 de agosto de 2026 Diario
ISCG · iShares Trust 0,50% 31 557 SH 8 de agosto de 2026 Diario
QVMM · Invesco Exchange-Traded Fund Trust … 0,49% 13 131 SH 8 de agosto de 2026 Diario
VBK · VANGUARD INDEX FUNDS 0,46% 1 331 820 SH 8 de agosto de 2026 Diario
IVOO · VANGUARD ADMIRAL FUNDS 0,46% 162 408 SH 8 de agosto de 2026 Diario
QLV · FlexShares Trust 0,46% 5 915 NS 30 de abril de 2026 N-PORT
IJH · iShares Trust 0,44% 3 469 295 SH 8 de agosto de 2026 Diario
SDG · iShares Trust 0,42% 4 563 SH 8 de agosto de 2026 Diario
FNY · First Trust Exchange-Traded AlphaDE… 0,40% 15 614 NS 30 de abril de 2026 N-PORT
IWP · iShares Trust 0,39% 493 090 SH 8 de agosto de 2026 Diario
PTMC · Pacer Funds Trust 0,39% 11 519 NS 30 de abril de 2026 N-PORT
USMV · iShares Trust 0,35% 534 448 SH 8 de agosto de 2026 Diario
MVV · ProShares Trust 0,34% 3 468 NS 31 de mayo de 2026 N-PORT
SXQG · EXCHANGE TRADED CONCEPTS TRUST 0,34% 1 461 NS 31 de mayo de 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,34% 16 076 NS 30 de abril de 2026 N-PORT
SCHM · SCHWAB STRATEGIC TRUST 0,29% 271 303 NS 31 de mayo de 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0,26% 1 662 NS 30 de abril de 2026 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,26% 40 014 NS 30 de abril de 2026 N-PORT
IYH · iShares Trust 0,26% 59 243 SH 8 de agosto de 2026 Diario
ISCB · iShares Trust 0,25% 4 488 SH 8 de agosto de 2026 Diario